Cargando…
Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al.
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Neoplasia Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924416/ https://www.ncbi.nlm.nih.gov/pubmed/35294914 http://dx.doi.org/10.1016/j.tranon.2022.101394 |
| _version_ | 1784669850982940672 |
|---|---|
| author | Hatırnaz Ng, Özden Eşkazan, Ahmet Emre |
| author_facet | Hatırnaz Ng, Özden Eşkazan, Ahmet Emre |
| author_sort | Hatırnaz Ng, Özden |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8924416 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Neoplasia Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89244162022-03-21 Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al. Hatırnaz Ng, Özden Eşkazan, Ahmet Emre Transl Oncol Commentary Neoplasia Press 2022-03-14 /pmc/articles/PMC8924416/ /pubmed/35294914 http://dx.doi.org/10.1016/j.tranon.2022.101394 Text en © 2022 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Commentary Hatırnaz Ng, Özden Eşkazan, Ahmet Emre Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al. |
| title | Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al. |
| title_full | Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al. |
| title_fullStr | Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al. |
| title_full_unstemmed | Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al. |
| title_short | Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al. |
| title_sort | tackling tki resistance in aml: a commentary on “inhibition of bcl2a1 by stat5 inactivation overcomes resistance to targeted therapies of flt3-itd/d835 mutant aml.” by yamatani et al. |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924416/ https://www.ncbi.nlm.nih.gov/pubmed/35294914 http://dx.doi.org/10.1016/j.tranon.2022.101394 |
| work_keys_str_mv | AT hatırnazngozden tacklingtkiresistanceinamlacommentaryoninhibitionofbcl2a1bystat5inactivationovercomesresistancetotargetedtherapiesofflt3itdd835mutantamlbyyamatanietal AT eskazanahmetemre tacklingtkiresistanceinamlacommentaryoninhibitionofbcl2a1bystat5inactivationovercomesresistancetotargetedtherapiesofflt3itdd835mutantamlbyyamatanietal |